NCT06171659View on ClinicalTrials.gov

FDG PET/MR Imaging of Peripheral Pain Generators

RecruitingOBSERVATIONAL
Enrollment

128

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
PainNociceptive Pain
Interventions
DRUG

FDG radiotracer

Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

DEVICE

PET/MRI

positron emission tomography and magnetic resonance imaging

DEVICE

PET/CT imaging

positron emission tomography and computed tomography imaging

Trial Locations (1)

53792

RECRUITING

UW School of Medicine and Public Health, Madison

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

collaborator

Arthroscopy Association of North America (AANA)

UNKNOWN

lead

University of Wisconsin, Madison

OTHER